Target Price | $575.83 |
Price | $563.95 |
Potential | 2.11% |
Number of Estimates | 25 |
25 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $575.83. This is 2.11% higher than the current stock price. The highest price target is $675.00 19.69% , the lowest is $470.00 16.66% . | |
A rating was issued by 34 analysts: 20 Analysts recommend Intuitive Surgical to buy, 13 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 2.11% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
26 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $9.7b . This is 10.82% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.8b 12.81% , the lowest is $9.5b 8.99% .
This results in the following potential growth metrics:
2024 | $8.4b | 17.24% |
---|---|---|
2025 | $9.7b | 15.63% |
2026 | $11.1b | 15.40% |
2027 | $12.9b | 15.42% |
2028 | $14.6b | 13.52% |
2029 | $16.0b | 9.26% |
21 Analysts have issued an Intuitive Surgical EBITDA forecast 2025. The average Intuitive Surgical EBITDA estimate is $3.9b . This is 33.25% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.8b 63.39% , the lowest is $3.3b 12.56% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $2.8b | 27.37% |
---|---|---|
2025 | $3.9b | 40.22% |
2026 | $4.5b | 15.44% |
2027 | $5.4b | 19.36% |
2028 | $6.4b | 17.52% |
2029 | $7.2b | 12.62% |
2024 | 33.58% | 8.64% |
---|---|---|
2025 | 40.72% | 21.26% |
2026 | 40.73% | 0.02% |
2027 | 42.12% | 3.41% |
2028 | 43.61% | 3.54% |
2029 | 44.95% | 3.07% |
11 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $2.5b . This is 0.63% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.7b 9.53% , the lowest is $2.3b 6.30% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.3b | 27.63% |
---|---|---|
2025 | $2.5b | 6.90% |
2026 | $2.9b | 19.74% |
2027 | $3.5b | 19.09% |
2028 | $4.1b | 16.62% |
2024 | 27.55% | 8.87% |
---|---|---|
2025 | 25.47% | 7.55% |
2026 | 26.43% | 3.77% |
2027 | 27.27% | 3.18% |
2028 | 28.01% | 2.71% |
11 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $6.86 . This is 0.59% higher than earnings per share in the financial year 2024. The highest EPS forecast is $7.47 9.53% , the lowest is $6.39 6.30% .
This results in the following potential growth metrics and future valuations:
2024 | $6.42 | 27.63% |
---|---|---|
2025 | $6.86 | 6.85% |
2026 | $8.22 | 19.83% |
2027 | $9.79 | 19.10% |
2028 | $11.41 | 16.55% |
Current | 82.72 | 18.56% |
---|---|---|
2025 | 82.17 | 0.66% |
2026 | 68.63 | 16.48% |
2027 | 57.62 | 16.04% |
2028 | 49.41 | 14.25% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 20.47 and an P/S ratio of 20.93 .
This results in the following potential growth metrics and future valuations:
Current | 22.69 | 25.36% |
---|---|---|
2025 | 20.47 | 9.77% |
2026 | 17.74 | 13.35% |
2027 | 15.37 | 13.36% |
2028 | 13.54 | 11.91% |
2029 | 12.39 | 8.47% |
Current | 23.19 | 23.75% |
---|---|---|
2025 | 20.93 | 9.76% |
2026 | 18.14 | 13.35% |
2027 | 15.71 | 13.36% |
2028 | 13.84 | 11.91% |
2029 | 12.67 | 8.47% |
Intuitive Surgical...
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Overweight
➜
Overweight
|
Unchanged | Apr 24 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
Baird |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Apr 23 2025 |
Evercore ISI Group |
In-Line
➜
In-Line
|
Unchanged | Apr 23 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Apr 23 2025 |
Baird |
Outperform
➜
Outperform
|
Unchanged | Mar 18 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Apr 24 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 23 2025 |
Unchanged
Baird:
Outperform
➜
Outperform
|
Apr 23 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Apr 23 2025 |
Unchanged
Evercore ISI Group:
In-Line
➜
In-Line
|
Apr 23 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Apr 23 2025 |
Unchanged
Baird:
Outperform
➜
Outperform
|
Mar 18 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.